Term ends Feb 9, 2038 · Medium confidence
20-year base term ends Feb 9, 2038
Why Medium: The disclaimer's references carry disclaimers of their own not yet read (US 12,005,042), so the cap could be lower.
Feb 9, 2018
Feb 9, 2038
Jun 17, 2025
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 0 of 3 maintenance fees are paid so far. Confidence: Medium. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Feb 9, 2018, when application PCT/GB2018/050374, the earliest non-provisional in its chain, was filed (this one was filed May 2, 2024) | Feb 9, 2038 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 11,357,753, US 12,005,042) | resolves to Feb 9, 2038, no earlier than this term, so no change | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Feb 9, 2038 | Medium confidence |
This family
| US 11,357,753 | In force Feb 2038 | Feb 2038 |
| US 12,005,042 | In force no later than Feb 2038 | no later than Feb 2038 |
| US 12,329,740 | this patent Feb 2038 | Feb 2038 |
| Application 19/211,545 | Pending not computed | not computed |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Oct 11, 2024 Reel 68873, frame 911 | Acacia Pharma Limited | Jpmorgan Chase Bank, N.a. | Security Interest |
| Apr 1, 2025 Reel 70698, frame 351 | JPMorgan Chase Bank, N.A., as Administrative Agent | Acacia Pharma Limited | Release of Security Interest |
| Mar 3, 2026 Reel 73958, frame 622 | Gilbert, Julian Clive; Gristwood, Robert William; Fox, Gabriel | Acacia Pharma Ltd. | Assignment of Assignor's Interest |
| Mar 4, 2026 Reel 73967, frame 303 | Acacia Pharma Limited; Acacia Pharma, Inc.; Eagle Pharmaceuticals, Inc. | Lxo Ireland Designated Activity Company; Lxo US, Inc. | Assignment of Assignor's Interest |
| Mar 4, 2026 reel/frame not recorded | Acacia Pharma Limited; Acacia Pharma, Inc.; Eagle Pharmaceuticals, Inc. | Lxo Ireland Designated Activity Company | Assignment of Assignor's Interest |
| Mar 4, 2026 reel/frame not recorded | Acacia Pharma Limited; Acacia Pharma, Inc.; Eagle Pharmaceuticals, Inc. | Lxo US, Inc. | Assignment of Assignor's Interest |
| Apr 27, 2026 Reel 74483, frame 163 | Lxo Ireland Designated Activity Company | Kroll Trustee Services Limited, as Security Agent | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer resolved from the filed document, referencing US 11,357,753, US 12,005,042, ends no earlier than this term, so it caps nothing.